Operational Update

The information contained within this announcement is deemed by Novacyt S.A. to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Operational Update

Paris, France, and Manchester, UK - 1 June 2026 Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces further proposed changes to its operating cost base.

Following the successful launch of a number of new products over the past 18 months and the recent acquisition of Southern Cross Diagnostics Pty Ltd, the Group is accelerating its plans to focus and streamline its operations and cost base.

The Company announces that it has begun a consultation process with certain members of staff across the Group which may result in a reduction of up to 40% in the Group's headcount (total headcount as at 26 May 2026 was circa 230). A further announcement will be released in respect of the outcome of the consultation process in due course.

Should the restructuring proceed, the associated labour and non-labour savings are expected to reduce the Group's annual cash burn by up to circa £4.0m, once all restructuring initiatives are complete. A cash restructuring charge of up to circa £1.0m is expected to be incurred. These numbers are conditional on the consultation process and assume the total reduction of 40%.